Effect of a Cysteinyl Leukotriene Receptor Antagonist on Experimental Emphysema and Asthma Combined with Emphysema
Authors:
- 1 January 2014
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 50 (1) , 18-29
Abstract
The incidence of overlapping bronchial asthma and chronic obstructive pulmonary disease has increased in recent years. Cysteinyl leukotrienes (CysLTs) play an important role in asthma, and the type 1 CysLT receptor (CysLT1R) is expressed by many inflammatory cells. We evaluated the effect of montelukast, a CysLT1R antagonist, on mouse models of asthma, porcine pancreatic elastase (PPE)-induced emphysema, and asthma combined with emphysema. Mice were sensitized with ovalbumin (OVA) on Days 0 and 14 and subsequently challenged with OVA on Days 28, 29, and 30. Pulmonary emphysema was induced by intratracheal instillation of PPE on Day 25. Mice were treated subcutaneously with montelukast or vehicle from Day 25 to Day 31. Airway hyperresponsiveness (AHR), static compliance; the number of inflammatory cells, the levels of cytokines, chemokines, LTs, and perforin in the bronchoalveolar lavage fluid, and the quantitative morphometry of lung sections were analyzed on Day 32. Treatment with montelukast significantly attenuated the AHR and eosinophilic airway inflammation in OVA-sensitized and OVA-challenged mice. Administration of montelukast significantly reduced the AHR, static compliance, and neutrophilic airway inflammation, while attenuating emphysematous lung changes, in PPE-treated mice. In PPE-treated mice subjected to allergen sensitization and challenges, montelukast significantly suppressed the AHR, static compliance, and eosinophilic and neutrophilic airway inflammation in addition to the development of experimentally induced emphysema in the lungs. Our data suggest that CysLT1R antagonists may be effective in ameliorating the consequences of PPE-induced lung damage and the changes that follow allergen sensitization and challenges.Keywords
This publication has 45 references indexed in Scilit:
- Requirement for Chemokine Receptor 5 in the Development of Allergen-Induced Airway Hyperresponsiveness and InflammationAmerican Journal of Respiratory Cell and Molecular Biology, 2011
- Blocking the Leukotriene B4 Receptor 1 Inhibits Late-Phase Airway Responses in Established DiseaseAmerican Journal of Respiratory Cell and Molecular Biology, 2011
- Structure–Function Relations in an Elastase-Induced Mouse Model of EmphysemaAmerican Journal of Respiratory Cell and Molecular Biology, 2011
- Concentration-Dependent Noncysteinyl Leukotriene Type 1 Receptor-Mediated Inhibitory Activity of Leukotriene Receptor AntagonistsThe Journal of Immunology, 2010
- The leukotriene E4 puzzle: Finding the missing pieces and revealing the pathobiologic implicationsJournal of Allergy and Clinical Immunology, 2009
- Leukotriene B4 Release from Mast Cells in IgE-Mediated Airway Hyperresponsiveness and InflammationAmerican Journal of Respiratory Cell and Molecular Biology, 2009
- Montelukast inhibits neutrophil pro‐inflammatory activity by a cyclic AMP‐dependent mechanismBritish Journal of Pharmacology, 2008
- IFN-γ Production during Initial Infection Determines the Outcome of Reinfection with Respiratory Syncytial VirusAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Chronic obstructive pulmonary disease * 3: Experimental animal models of pulmonary emphysemaThorax, 2002
- Characteristics of formation and further metabolism of leukotrienes in the chopped human lungBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990